- Home
- GALT vs ZTR Comparison
GALT vs ZTR Comparison
Compare GALT & ZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.54
Company Overview
Basic Information| Metric | GALT | ZTR |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.0M | 342.5M |
| IPO Year | 2008 | 1995 |
Fundamental Metrics
Financial Performance| Metric | GALT | ZTR |
|---|---|---|
| Price | $3.54 | $6.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 218.5K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.03 | $6.14 |
| 52 Week High | $7.13 | $7.11 |
Technical Indicators
Market Signals| Indicator | GALT | ZTR |
|---|---|---|
| Relative Strength Index (RSI) | 45.02 | 54.57 |
| Support Level | $2.30 | $6.68 |
| Resistance Level | $4.35 | $6.93 |
| Average True Range (ATR) | 0.49 | 0.07 |
| MACD | -0.18 | -0.00 |
| Stochastic Oscillator | 9.01 | 56.67 |
Price Performance
Historical Comparison GALT
ZTR
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.